Atrial Fibrillation, Embolism Thrombosis
Conditions
Keywords
apixaban, endogenous fibrinolysis, warfarin, aspirin, thrombotic status
Brief summary
This study will assess the effect of apixaban on thrombotic status in patients with atrial fibrillation.In addition it will compare apixaban to aspirin and warfarin on their effect on endogenous fibrinolysis.
Detailed description
Patients with an irregular heart rhythm called atrial fibrillation (AF) have an increased risk of forming blood clots inside the heart, that can then fragment and break off, travelling through the circulation to the brain, where it can cause blockage of the small blood vessels resulting in a stroke. Most patients with AF are prescribed blood thinning medications in an attempt to prevent such clot formation. The body has the ability through enzymes circulating in blood, to dissolve a clot once formed, such that even if a clot is formed, it is rapidly dissolved and no lasting damage is sustained. This is known as endogenous fibrinolysis. If this defence system is faulty or suboptimal, there is an increased risk of clot formation, resulting in stroke or heart attack. Currently, there are no available tablets to favourably modify this defence system of endogenous fibrinolysis. The investigators will assess how this defence system functions in patients with AF who are on different blood thinners. Then the investigators will also assess a group of patients before and during treatment with a relatively new blood thinner called apixaban, to assess the effect of this on the stickiness of blood and the ability of the blood to dissolve clots (endogenous fibrinolysis). All the blood thinners will be prescribed for clinical indications, not as part of the research. The research aspect of the study is that we will perform a blood test to assess endogenous fibrinolysis. Understanding the effect of apixaban on endogenous fibrinolysis raises the possibility that apixaban, rather than other blood thinners, may be of particular use in patients with impaired fibrinolysis who are at particularly high risk of clots due to inefficient endogenous fibrinolysis.
Interventions
OTHERThrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
Sponsors
University of Hertfordshire
East and North Hertfordshire NHS Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>18 years 2. Diagnosis of NVAF (nonvalvular atrial fibrillation) 3. Requiring anticoagulation or antiplatelet therapy for thromboprophylaxis of stroke and systemic embolism 4. No contra-indications to apixaban (except for those patients taking part in baseline cross-sectional study where this inclusion criterion does not apply) 5. Patient does not meet any of the
Exclusion criteria
below
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessing the effect of apixaban on endogenous fibrinolysis in patients wth atrial fibrillation | Change of endogenous fibrinolysis from baseline at 4 weeks | Measuring endogenous fibrinolysis before and after apixaban |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparing the effect of apixaban to warfarin and aspirin on endogenous fibrinolysis in patients with atrial fibrillation | 12 months | Compare the effect on endogenous fibrinolysis as measured by occlusion time and lysis time (seconds) of stable apixaban, warfarin and aspirin treatment in patients with atrial fibrillation with the GTT,TEG,thrombin generation assays |
Countries
United Kingdom
Outcome results
None listed